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Abstract
Background: Polymorphisms in Epidermal Growth Factor Receptor (EGFR) gene may influence
EGFR production and/or activity, thereby modulating susceptibility to lung cancer. To test this
hypothesis, we investigated the association between polymorphisms in the EGFR gene and the risk
of lung cancer in a Korean population.
Methods: We first examined the frequencies of 39 candidate polymorphisms in the EGFR gene in
27 healthy Korean individuals. After then, we genotyped five polymorphisms (127378C>T,
142285G>A, 162093G>A, 181946C>T and 187114T>C) that have variant allele frequencies
greater than 10%, in 582 lung cancer patients and in 582 healthy controls.
Results: Of the 5 polymorphisms, the 181946C>T genotype distribution was significantly different
between the cases and controls (P = 0.04). Compared with the 181946 CC + CT genotype, the
181946 TT genotype was associated with a significantly decreased risk of lung cancer (adjusted OR
= 0.63, 95% CI = 0.45–0.88, P = 0.007). When the analyses were stratified by smoking status, the
protective effect of the TT genotype was statistically significant in ever-smokers (adjusted OR =
0.59, 95% CI = 0.41–0.86, P = 0.007), but not in never-smokers (adjusted OR = 0.89, 95% CI =
0.45–1.75, P = 0.73; P = 0.08, test for homogeneity). Consistent with the results of the genotyping
analysis, the CGGCT haplotype with the 181946C allele was associated with a significantly
increased risk of lung cancer compared to the CGGTT haplotype carrying the 181946T allele
(adjusted OR = 1.50, 95% CI = 1.09–2.07, P = 0.012 and Bonferroni corrected P-value = 0.048).
Conclusion: These results suggest that the EGFR polymorphisms, particularly the 181945C>T
polymorphism, could be used as markers for the genetic susceptibility to lung cancer.
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Background
The development and progression of lung cancer is a
multi-step process characterized by the accumulation of
multiple genetic and epigenetic alterations, that results in
perturbations of cell-regulatory and growth-control path-
ways [1,2]. The epidermal growth factor receptor (EGFR)-
driven pathway is known to be one of the known impor-
tant oncogenic signang cascades in lung cancer [2-4].
The EGFR is a tyrosine kinase receptor that belongs to the
ERBB family, and it mediates the intracellular effects of
growth factors such as EGF, transforming growth factor α
and neuregulins. The activation of EGFR via overexpres-
sion of the receptor and/or ligands or its structural altera-
tion, affects a number of processes important to cancer
development and progression, including cell prolifera-
tion, apoptosis, angiogenesis, and metastasis [5-7].
Single nucleotide polymorphisms (SNPs) are the most
common sources of human genetic variation, and they
may contribute to an individuals' susceptibility to cancer.
Several studies have demonstrated that some variants
affect either the expression or activities of various
enzymes, and that they are therefore associated with the
risk of cancer development [8-11]. Several polymor-
phisms in the EGFR gene have been reported [12-16] and
deposited into public databases [17]. Although the func-
tional effects of these polymorphisms have not yet been
fully elucidated, we hypothesized that some of these vari-
ants may have an effect on EGFR expression or activity,
and therefore may play a role in modulating the suscepti-
bility to lung cancer. To test this hypothesis, we performed
a case-control study to investigate the association between
EGFR genotypes/haplotypes and the risk of lung cancer.
Methods
Identification and selection of polymorphisms
Among the candidate polymorphisms in the EGFR gene,
we initially captured 39 SNPs in the promoter region, all
exons including intron-exon boundaries (10 bp of the
introns on either side) and the 3'-UTR of the gene because
variants in these regions are most likely to affect gene
function (Table 1). We then examined the frequencies of
the captured SNPs in a preliminary study that included 27
healthy controls and 27 lung cancer cases. Among the 39
captured SNPs, seven SNPs [127378C>T (rs2072454),
142232C>T (rs17336800), 142285G>A (rs11543848),
151904T>A (rs17290169), 162093G>A (rs10251977),
181946C>T (rs2293347), and 187114T>C (rs884225)]
had minor allele frequencies greater than 10% in the 54
subjects. The 142232C>T and 151904T>A were com-
pletely or near completely linked with the 142285G>A.
Thus five SNPs (127378C>T, 142285G>A, 162093G>A,
181946C>T and 187114T>C) were chosen for the associ-
ation study.
Study population
This case-control study included 582 lung cancer patients
and 582 healthy controls (Table 2), and the details of the
study population have been described previously [18,19].
In brief, the eligible cases included all patients who were
newly diagnosed with primary lung cancer between Janu-
ary 2001 and June 2002 at Kyungpook National Univer-
sity Hospital, Daegu, Republic of Korea. There were no
age, gender, histological, or stage restrictions, but patients
with a prior history of cancer were excluded from the
study. The cases included 270 (46.4%) squamous cell car-
cinomas, 205 (35.2%) adenocarcinomas, 97 (16.7%)
small cell carcinomas, and 10 (1.7%) large cell carcino-
mas. The control subjects were randomly selected from a
pool of healthy volunteers who visited the general health
check-up center at Kyungpook National University Hospi-
tal during the same period. A total of 3065 (1598 males
and 1467 females) of 5578 healthy subjects agreed to par-
ticipate in this study (participation rate, 54.9%). Com-
pared with subjects that refused to participate, enrolled
subjects showed similar sex (% of male, 52.5% versus
52.1%; P = 0.80) and age (52.2 ± 11.4 versus 52.1 ± 11.3;
P = 0.80) distributions. From 3065 healthy volunteers, we
randomly selected 582 control subjects that were fre-
quency-matched (1:1) to the cases based on sex and age (±
5 years). All of the cases and the controls were ethnic Kore-
ans and they resided in Daegu City or the surrounding
regions. This study was approved by the institutional
review board of the Kyungpook National University Hos-
pital, and written informed consent was obtained from
each participant.
EGFR genotyping
Genomic DNA was extracted from peripheral blood lym-
phocytes by proteinase K digestion and phenol/chloro-
form extraction. The EGFR  127378C>T, 142285G>A
(R521K), 162093G>A (N158N), 181946C>T (Q787Q)
and 187114T>C genotypes were determined using a PCR-
RFLP assay. PCR primers were designed based on the Gen-
Bank reference sequence (accession no. NT_033968). The
PCR primers for 127378C>T, 142285G>A, 162093G>A,
181946C>T and 187114T>C polymorphisms were 5'-
ATTGCGGGACTCTTGTTCGC-3' (forward) and 5'-
CGCCACTGGATGCTCTCCG (mutated A→G)C-3'
(reverse); 5'-TCCCTGCTCTGTCACTGACT-3' (forward)
and 5'-T AACAACAACCTGGAGCCTT-3' (reverse); 5'-
TGCCTCACCTCCACCGTGG (mutated C→G)A-3' (for-
ward) and 5'-GCACGCACACACATATCCCC-3' (reverse);
5'-ATTGG CAAACACACAGGCAC-3' (forward) and 5'-
CTGCTGAAGAA GCCCTGCTG-3' (reverse); and 5'-
AGAAACGGAGGGGATGGAAT-3' and 5'-AGGTATTCCA-
CATTCT CAGC-3' (reverse), respectively. PCR reactions
were performed in a 20 µl reaction volume containing
100 ng genomic DNA, 10 pM of each primer, 0.2 mM
dNTPs, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mMBMC Cancer 2007, 7:199 http://www.biomedcentral.com/1471-2407/7/199
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MgCl2, 5% DMSO and 1 unit of Taq polymerase (Takara
Shuzo Co., Otsu, Shiga, Japan). The PCR cycle conditions
consisted of an initial denaturation step at 95°C for 5 min
followed by 35 cycles of 30 s at 94°C 30 s at 58°C for
127378C>T and 187114T>C, 54°C for 142285G>A,
57°C for 162093G>A, and 56°C for 181946C>T; 30 s at
72°C; and a final elongation at 72°C for 10 min. The PCR
products were digested overnight with the appropriate
restriction enzymes (New England BioLabs, Beverly, MA,
USA) at 60°C (127378C>T) or 37°C (162093G>A,
142285G>A, 181946C>T and 187114T>C). The restric-
tion enzymes for 127378C>T, 142285G>A, 162093G>A,
181946C>T and 187114T>C genotypes were BstUI, BstNI,
BanII, MlyI, and AciI, respectively. The digested PCR prod-
ucts were resolved on 6% acrylamide gel and stained with
ethidium bromide for visualization under UV light. To
ensure quality control, the genotyping analysis was per-
formed "blind" with respect to case/control status. About
Table 1: Known and candidate polymorphisms in the EGFR gene
Variant allele frequency†
Region† Nucleotide (amino acid) change† SNP ID† Korean (27 controls/27 cases) Global Caucasian Asian African American
Promoter -1433C>T rs17335689 0.00/0.00 0.017 0.00 0.00 0.042
-1298G>A rs17335696 0.00/0.00 0.006 0.00 0.00 0.042
-1247G>A rs6593197 0.00/0.00 - 0.00 0.00 0.104
-1225G>A - 0.00/0.00 - 0.023 0.00 0.00
-759C>A rs759171 0.00/0.00 0.101 0.136 0.00 0.146
-646G>A - 0.00/0.00 - 0.00 0.00 0.042
-615C>G rs13228815 0.00/0.00 - - - -
-540G>A - 0.02/0.00 - 0.00 0.024 0.00
-482C>A rs17335710 0.00/0.00 0.006 0.00 0.00 0.063
-216G>T rs712829 0.02/0.04 0.222 0.318 0.071 0.292
-191C>A rs712830 0.00/0.00 0.078 0.136 0.00 0.00
Intron 1 169G>T rs17335738 0.00/0.00 0.101 0.114 0.00 0.114
2028G>A - 0.07/0.07 - 0.023 0.095 0.042
Exon 3 124080G>A (R98Q) rs17289589 0.00/0.00 0.006 - - -
Exon 4 127378C>T (N158N) rs2072454 0.37/0.32 0.415 0.500 (0.42)‡ 0.320 0.457
127417C>T (D171D) rs17289686 0.00/0.00 0.011 - - -
127435G>A (S177S) rs17336437 0.00/0.00 0.028 - - -
Intron 4 127473G>A IVS4+10) rs7801956 0.00/0.02 0.051 0.070 0.039 0.008
Exon 7 134783C>G (P266R) rs17336639 0.00/0.00 0.006 - - -
Exon 8 136584C>T (C307C) rs17289893 0.00/0.00 0.011 - - -
Exon 9 137368G>A (P373P) rs2302536 0.00/0.00 0.006 0.00 0.007 -
Exon 12 140880G>A (A439A) rs17290005 0.00/0.00 0.022 - - -
Exon 13 142232C>T (G503G) rs17336800 0.39/0.41 0.006 - - -
142285G>A (R521K) rs11543848 0.39/0.41 0.289 0.250 (0.26)‡ 0.500 0.109
Exon 14 144456T>C (G544G) rs17290103 0.00/0.00 0.022 - - -
Exon 15 146055T>C (V592A) rs28384375 0.00/0.00 - - - -
146068G>A (P596P) rs17290162 0.00/0.00 0.017 - - -
146119C>T (A613A) rs17290169 0.00/0.00 0.08 - (0.05)‡ --
146151G>T (C624F) rs28384376 0.00/0.00 - - - -
Exon 16 151904T>A (T629T) rs17337023 0.37/0.41 0.456 - (0.36)‡ - (0.446)§ -
Exon 17 153806G>A (V674I) rs17337079 0.00/0.00 0.006 - - -
Exon 18 154737G>T (G719C) rs28929495 0.00/0.00 - - - -
Exon 20 162093G>A (Q787Q) rs10251977 0.07/0.13 0.427 0.604 (0.48)‡ 0.146 0.457
Exon 21 172480C>T (R836R) rs17518376 0.00/0.00 0.011 0.083 (0.07)‡ 0.00 0.00
Exon 23 179447T>C (T903T) rs1140475 0.07/0.06 0.111 0.117 (0.13)‡ 0.06 0.017
Exon 24 181074C>G (R962G) rs17337451 0.00/0.00 0.06 - - -
Exon 25 181927A>C (H988P) rs17290699 0.00/0.00 0.006 - - -
181946C>T (D994D) rs2293347 0.43/0.35 0.197 0.136 0.286 0.053
3'UTR 187114T>C rs884225 0.37/0.31 0.869 0.150 0.475 0.025
† Information about SNPs, SNP ID and frequencies of variant alleles in other ethnic populations were obtained from NCBI database http://
www.ncbi.nlm.nih.gov. In the reference sequence (GenBank accession no. NT_033968), the translation start site was counted as +1. In the cases of 
polymorphisms in the promoter and intron 1 (i.e., from -1433C>T to 2028G>A), frequencies of variant alleles in Caucasians, Asians and African 
Americans were obtained from Ref. 15.
‡ Data in the parenthesis were obtained from Ref. 14.
§ Datum in the parenthesis was obtained from Ref. 24.BMC Cancer 2007, 7:199 http://www.biomedcentral.com/1471-2407/7/199
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10% of the samples were randomly selected to be geno-
typed again by a different investigator, and the results
were 100% concordant. Information about all SNPs, SNP
ID and allele frequency was obtained from the NCBI
homepage [17]. In the reference sequence, the translation
start site was counted as +1.
Statistical analysis
The cases and controls were compared using the Student's
t-test for continuous variables and a χ2 test for categorical
variables. Hardy-Weinberg equilibrium was tested using a
goodness-of-fit χ2 test with one degree of freedom to com-
pare observed genotype frequencies with expected geno-
type frequencies among the subjects. The strength of LD
between pairs of polymorphisms was measured by Hap-
loView [20]. The haplotypes and their frequencies were
estimated based on a Bayesian algorithm using the Phase
program [21]. Conditional logistic regression analysis was
used to calculate odds ratios (ORs) and 95% confidence
intervals (CIs) for overall lung cancer, with adjustment of
pack-years of smoking (as a continuous variable). In addi-
tion to the overall association analysis, we performed a
stratified analysis by age (median age, ≤ 62 years/>62
years), gender, smoking status, cigarette exposure level
(median pack-years of smoking in ever-smokers, ≤ 38
pack-years/>38 pack-years), and tumor histology to fur-
ther explore the association between EGFR  genotypes/
haplotypes and the risk of lung cancer in each stratum.
The ORs and 95% CIs in the stratification analyses were
calculated using unconditional logistic regression analy-
sis, with adjustment for gender, age or pack-years of smok-
ing, when appropriate. The interaction between genotype
and smoking was tested both with a logistic regression
model that included the interaction term between geno-
type and smoking (pack-years of smoking or smoking
exposure level), and by stratification analysis. The interac-
tion term between genotype and smoking was not statisti-
cally significant, and this was removed from the logistic
regression model. When multiple comparisons were
made, the Bonferroni inequality method was used to cal-
culate the corrected P-values (Pc-values) for multiple test-
ing. All the analyses were performed using Statistical
Analysis Software for Windows, version 8.12 (SAS insti-
tute, Gary, NC, USA).
Results
The genotype frequencies of the EGFR  127378C>T,
142285G>A, 162093G>A, 181946C>T and 187114T>C
polymorphisms among the cases and controls and their
association with lung cancer risk are shown in Table 3.
The genotype distributions of the 127378C>T,
142285G>A, 162093G>A, 181946C>T and 187114T>C
polymorphisms among the controls were in Hardy-Wein-
berg equilibrium (χ2 = 0.004, P = 0.95; χ2 = 0.98, P = 0.32;
χ2 = 1.19, P = 0.28; χ2 = 1.26, P = 0.26; and χ2 = 0.15, P =
0.70, respectively). The distribution of the 181946C>T
genotypes was significantly different between the cases
and controls (CC, CT and TT genotypes; 41.6%, 46.1%
and 12.4% vs 36.8%, 45.9% and 17.4%; P = 0.04), with
the frequency of the variant T allele being significantly
lower in the cases than in the controls (35.5% vs 40.4%,
P = 0.01). Compared with the 181946 CT + CC genotype,
the 181946 TT genotype was associated with a signifi-
cantly decreased risk of lung cancer (adjusted OR = 0.63,
95% CI = 0.45–0.88, P = 0.007). There was no significant
difference in the genotype distributions of the other four
polymorphisms studied between the cases and controls.
The association between the EGFR 181946C>T genotypes
and the risk of lung cancer was further examined after
stratification according to gender, age, smoking status,
and histologic types of lung cancer. The effect of the TT
genotype on the risk of lung cancer was similar in males
and females, as well as in younger- and older-individuals
(data not shown). When the analyses were stratified by
smoking status, the protective effect of the TT genotype
was statistically significant in ever-smokers (adjusted OR
= 0.59, 95% CI = 0.41–0.86, P = 0.007; Table 4) but not
in never-smokers (adjusted OR = 0.89, 95% CI = 0.45–
1.75, P = 0.73; P = 0.08, test for homogeneity). Lung can-
cers are composed of heterogeneous histological types,
and the pathways of carcinogenesis differ according to the
histological types of lung cancer. Therefore, the effect of
the EGFR 181946C>T genotype on the risk of lung cancer
was estimated according to the histological type of lung
cancer. The protective effect of the TT genotype was pro-
nounced in patients with small cell lung carcinoma and
squamous cell carcinoma (adjusted OR = 0.32, 95% CI =
0.14–0.73, P = 0.007; and adjusted OR = 0.65, 95% CI =
0.41–1.01, P = 0.06, respectively).
We estimated the EGFR haplotypes of the 127378C>T,
142285G>A, 162093G>A, 181946C>T, and 187114T>C
polymorphisms in the cases and controls, separately, and
Table 2: Characteristics of the study population
Variable Cases (n = 582) Controls (n = 582)
Age (years) 61.3 ± 9.4 60.2 ± 9.6
Sex
Male 467 (80.2)a 467 (80.2)
Female 115 (19.8) 115 (19.8)
Smoking statusb
Current 387 (66.5) 297 (51.0)
Former 85 (14.6) 147 (25.3)
Never 110 (18.9) 138 (23.7)
Pack-yearsc 40.0 ± 17.7 34.1 ± 17.8
a Numbers in parenthesis, percentage.
b P < 0.001.
c In current and former smokers, P < 0.001BMC Cancer 2007, 7:199 http://www.biomedcentral.com/1471-2407/7/199
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Table 3: EGFR genotypes of cases and controls, and their association with the risk of lung cancer
Genotypes Cases (n = 582), no. Controls(n = 582), no. P ‡ Crude OR (95% CI) Adjusted OR¶ (95% CI)
M/F† Overall(%) M/F† Overall(%)
127378C>T
CC 194/59 253 (43.5) 196/61 257 (44.2) 0.61 1.00 1.00
CT 208/45 253 (43.5) 216/44 260 (44.7) 0.99(0.77–1.26) 1.00(0.78–1.28)
TT 65/11 76 (13.1) 55/10 65 (11.2) 1.19(0.82–1.73) 1.22(0.83–1.78)
T allele 0.348 0.335 0.51
142285G>A
GG 166/40 206 (35.4) 161/54 215 (36.9) 0.80 1.00 1.00
GA 218/61 279 (47.9) 224/44 268 (46.1) 1.09(0.84–1.40) 1.11(0.86–1.44)
AA 83/14 97 (16.7) 82/17 99 (17.0) 1.02(0.73–1.44) 1.05(0.74–1.48)
A allele 0.406 0.400 0.77
162093G>A
GG 337/89 426 (73.2) 343/86 429 (73.7) 0.54 1.00 1.00
GA 117/26 143 (24.6) 117/28 145 (24.9) 0.99(0.76–1.30) 0.96(0.73–1.26)
AA 13/0 13 (2.2) 7/1 8 (1.4) 1.64(0.67–3.99) 1.60(0.65–3.97)
A allele 0.145 0.138 0.63
181946C>T
CC 195/47 242 (41.6) 181/33 214 (36.8) 0.04 1.00 1.00
CT 221/47 268 (46.1) 212/55 267 (45.9) 0.89(0.69–1.14) 0.89(0.69–1.15)
TT 51/21 72 (12.4) 74/27 101 (17.4) 0.63(0.44–0.90)* 0.59(0.41–0.85)**
CC+CT 416/94 510 (87.6) 393/88 481 (82.6) 0.02 1.00 1.00
TT 51/21 72 (12.4) 74/27 101 (17.4) 0.67(0.49–0.93)* 0.63(0.45–0.88)***,****
T allele 0.354 0.403 0.01
187114T>C
TT 162/42 204 (35.1) 163/42 205 (35.2) 0.78 1.00 1.00
TC 215/54 269 (46.2) 219/58 277 (47.6) 0.98(0.76–1.26) 1.01(0.78–1.31)
CC 90/19 109 (18.7) 90/15 100 (17.2) 1.10(0.79–1.53) 1.16(0.83–1.63)
C allele 0.418 0.410 0.71
† Male/Female.
‡ Two-sided χ2 test for either genotype distributions or allele frequencies between the cases and controls.
¶ ORs (95% CIs) were calculated by conditional logistic analysis, adjusted for pack-years of smoking.
* P = 0.01.
** P = 0.005.
*** P = 0.007.
**** P = 0.32 for the interaction term between genotype and smoking status in the multivariate analysis.
Table 4: Stratification analysis of the EGFR 181946C>T genotype frequencies in cases and controls
Variable Genotype, no (%)
Cases Controls Adjusted OR (95% CI)
CC + CT TT CC+TT TT CC+TT TT P
Smoking status
Never 91 (82.7) 19 (17.2) 114 (82.6) 24 (17.4) 1.0 0.89 (0.45–1.75)† 0.73
Ever‡ 419 (88.8) 53 (11.2) 367 (82.7) 77 (17.3) 1.0 0.59 (0.41–0.86)†, * 0.007
≤ 38 pys 168 (88.4) 22 (11.6) 226 (84.0) 43 (16.0) 1.0 0.64 (0.37–1.12)† 0.12
> 38 pys 251 (89.0) 31 (11.0) 141 (80.6) 34 (19.4) 1.0 0.52 (0.30–0.88)† 0.01
Histologic types§
Squamous cell ca. 238 (88.1) 32 (11.9) 481 (82.6) 101 (17.4) 1.0 0.65 (0.41–1.01)¶
Adenoca. 173 (84.4) 32 (15.6) 481 (82.6) 101 (17.4) 1.0 0.82 (0.52–1.28)¶
Small cell ca. 90 (92.8) 7 (7.2) 481 (82.6) 101 (17.4) 1.0 0.32 (0.14–0.73)¶
† Adjusted for age and pack-years of smoking.
‡ Current and former smoker.
§ Ten large cell carcinoma cases were excluded from this analysis.
¶ Adjusted for gender and pack-years of smoking.
* P = 0.08, test for homogeneity test between genotype-related ORs of never- and ever-smokers.BMC Cancer 2007, 7:199 http://www.biomedcentral.com/1471-2407/7/199
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we compared their frequency distributions between the
cases and controls. The five polymorphisms were not in
strong LD (Fig. 1), and thus established 29 out of the 32
(25) potential haplotypes. The 25 haplotypes that had a
frequency of less than 5% were pooled into a single group
and included in the haplotype analysis. Table 5 shows the
inferred haplotype distribution for the controls and cases,
and the lung cancer risk related to each haplotype.
Because the 181946TT genotype had a significant protec-
tive effect against lung cancer in the logistic regression
analysis for each polymorphism, the adjusted ORs and
95% CIs were calculated using the CGGTT haplotype with
the 181946T allele as the reference group. Compared to
the CGGTT haplotype, the CGGCT haplotype, which is
one of three haplotypes carrying the 181946C allele, was
associated with a significantly increased risk of lung can-
cer (adjusted OR = 1.50, 95% CI = 1.09–2.07, P = 0.012,
Pc = 0.048).
Discussion
DNA sequence variations in the EGFR gene may lead to
alteration in the production and/or activity of the EGFR,
thereby causing interindividual differences in lung cancer
susceptibility. To test this hypothesis, we evaluated the
potential association of five EGFR  polymorphisms
(127378C>T, 142285G>A, 162093G>A, 181946C>T and
187114T>C) and the risk of lung cancer. In addition, the
EGFR haplotypes composed of five polymorphisms were
estimated, and their frequency distributions in the lung
cancer cases and controls were compared. Of the five pol-
ymorphisms studied, the 181946C>T polymorphism was
associated with a significantly decreased risk of lung can-
cer. This finding suggests that this polymorphism might
be a useful marker for determining genetic susceptibility
to lung cancer.
When studying polymorphisms using a limited number
of subjects, low minor allele frequencies of the polymor-
phism may lead to null result although the polymor-
phism is meaningful for the risk of target disease [22-24].
In order to identify common variants (frequencies above
10%), we first determined the frequencies of the 39
reported polymorphisms in a preliminary study that
included 27 healthy Koreans and 27 lung cancer cases. In
the present study, we validated the presence of 11 poly-
morphisms in a Korean population: -540G>A, -216G>T,
2028G>A, 127378C>T, 142232C>T, 142285G>A,
151904T>A, 162093G>A, 179447T>C, 181946C>T and
187114T>C. However, the other 28 candidate polymor-
Linkage disequilibrium values |D'| (× 100) between EGFR pol- ymorphisms among 582 healthy Koreans Figure 1
Linkage disequilibrium values |D'| (× 100) between EGFR pol-
ymorphisms among 582 healthy Koreans.
Table 5: EGFR haplotype frequencies in the cases and controls, and their association with lung cancer risk
Haplotype† Controls (n = 1164) Cases (n = 1164)
no. (%) no. (%) Adjusted§ OR (95% CI) P
CGGCT 91 (7.8) 118 (10.1) 1.50 (1.09–2.07) 0.012*
CGGCC 124 (10.7) 110 (9.5) 1.08 (0.80–1.47) 0.60
CGGTT 350 (30.1) 305 (26.2) 1.00
TAGCC 227 (19.5) 234 (20.1) 1.24 (0.97–1.58) 0.09
Others‡ 372 (32.0) 397 (34.1) 1.24 (0.98–1.54) 0.07
Global P 0.08
† The order of polymorphisms is as follows: 117378C>T, 142285G>A, 162093G>A, 181946C>T and 187114T>C.
‡ Twenty-five haplotypes that had a frequency of less than 5%.
§ Adjusted for age, gender and pack-years of smoking.
* Bonferroni corrected P-value = 0.048.BMC Cancer 2007, 7:199 http://www.biomedcentral.com/1471-2407/7/199
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phisms listed in Table 1 were not detected in the prelimi-
nary study. Considering the sample size of the study, the
127378C>T, 142232C>T, 162093G>A, 181946C>T and
187114T>C that have variant allele frequencies > 10%
were subjected to a case-control study to examine their
association with lung cancer risk.
A few studies have investigated the association between
EGFR polymorphisms and the risk of human cancer [25-
27]. A (CA)n dinucleotide repeat polymorphism in intron
1 of the EGFR gene has been shown to affect the basal
transcription activity of the EGFR gene; subjects with short
CA repeats have been shown to have increased EGFR
expression [28,29]. Moreover, Kang et al. [25] reported
that Puerto Rican subjects having a lower number of CA
repeats showed an increased risk of oral cancer. In con-
trast, we found that this dinucleotide polymorphism does
not significantly contribute to the genetic susceptibility to
lung cancer in Koreans [26], and we therefore excluded
this polymorphism from the current study. In addition to
the (CA)n repeat polymorphism, the -216G>T polymor-
phism, located in a Sp1 recognition site of the EGFR pro-
moter, has been shown to increase the promoter activity
by 30% [15]. This polymorphism has also been associated
with an increased risk of glioblastoma in a European Cau-
casian population [27]. Despite its functional signifi-
cance, the -216G>T polymorphism was not included in an
association analysis in the present study because the fre-
quency of the -216G>T polymorphism was rare (1.9%)
among the 27 healthy Koreans in the preliminary study.
Therefore, additional studies with larger sample sizes are
needed to determine the effect of the -216G>T polymor-
phism on the risk of lung cancer in a Korean population.
A nonsynonymous 142285G>A (R521K) polymorphism,
located in the extracellular ligand-binding domain of the
EGFR gene has been shown to decrease ligand binding
affinity, thus attenuating growth stimulation, tyrosine
kinase activation and the induction of protooncogenes
such as FOS, JUN, and MYC [13]. In the present study,
however, this nonsynonymous polymorphism was not
associated with the risk of lung cancer. The frequency of
the variant 521K allele reported in the NIH database [17]
shows remarkable variation between different ethnic
groups (0.109 of African Americans, 0.250 of Caucasians,
and 0.500 of Asians). Therefore, further studies are
needed to clarify the association between the R521K pol-
ymorphism and lung cancer in different ethnic popula-
tions.
In the present study, individuals carrying the 181946 TT
genotype were at a significantly decreased risk of lung can-
cer in comparison to those individuals with the 181946
CT or CC genotype. The mechanism underlying the asso-
ciation between the 181946C>T polymorphism and lung
cancer risk remains to be elucidated. Because the
181946C>T polymorphism does not result in an amino
acid change, nor does it reside within the functional
domain, the observed effect of the 181946C>T polymor-
phism on lung cancer may be due to LD with other func-
tional EGFR variant(s) that were not tested in this study.
Therefore, additional studies are needed to detect the
other functional variants in the EGFR gene and their asso-
ciations with lung cancer.
Another interesting finding of this study was an interac-
tion between the EGFR polymorphism and tobacco smok-
ing. The EGFR  181946C>T polymorphism was
significantly associated with the risk of lung cancer in the
smokers but not in the never-smokers, which reflects a
gene-environment interaction. However, because the
interaction term between the genotype and smoking was
not statistically significant in the multivariate logistic
regression analysis (P = 0.32 for the interaction term), the
failure to observe a significant effect in never-smokers
might be due to the relatively small number of subjects in
this group. Therefore, additional studies must be con-
ducted with a greater number of subjects in order to con-
firm these findings.
Recent studies have demonstrated that the haplotype has
greater power to detect disease associations than an indi-
vidual polymorphism on account of LD with the disease-
causative variants. In addition, haplotype analysis offers
the advantages of not assuming that any of the genotyped
polymorphisms are functional, and it allows for the pos-
sibility of an ungenotyped functional variant to be in LD
with the genotyped polymorphisms [30-32]. Therefore,
our investigation was extended to analyze the EGFR hap-
lotypes composed of the 127378C>T, 142285G>A,
162093G>A, 181946C>T and 187114T>C polymor-
phisms. In the haplotype analysis, only one (the CGGCT
haplotype) of the three haplotypes carrying the 181946C
allele was associated with a significantly increased risk of
lung cancer in comparison to the CGGTT haplotype with
the 181946T allele. These results also suggest that haplo-
type analysis may be a more suitable tool for assessing the
disease-association than the individual polymorphism.
However, the result of this haplotype analysis should be
interpreted with caution due to a limitation of the compu-
tational methods used for haplotype estimation. The
computational methods can be used to effectively and
accurately predict haplotypes in genetic regions with pro-
nounced LD but not in regions where marked LD is not
maintained [33,34]. Therefore, since the five EGFR poly-
morphisms studied were not in strong LD, it is possible
that there may have been an estimation error in the EGFR
haplotype estimation. In addition, because this study was
designed to evaluate the effects of EGFR polymorphisms
on the risk of overall lung cancer, the stratification analy-BMC Cancer 2007, 7:199 http://www.biomedcentral.com/1471-2407/7/199
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ses according to age, gender, smoking status and tumor
histology might have a type I error (due to multiple com-
parisons) and/or a type II error (due to the small number
of subjects in the subgroups). Therefore, additional stud-
ies with larger sample sizes are required to confirm our
findings.
Conclusion
In this study, we tested the hypothesis that polymor-
phisms in the EGFR gene can affect the risk of lung cancer
in the general population. We found that the 181946C>T
polymorphism was associated with the risk of lung cancer.
This result suggests that the EGFR 181946C>T polymor-
phism could be used as a marker for the genetic suscepti-
bility to lung cancer; however, additional studies with
larger sample sizes are needed to confirm our findings.
Future studies on the other EGFR sequence variants and
their biological function are also needed in order to
understand the role of the 181946C>T polymorphism in
determining the risk of lung cancer. Moreover, because
genetic polymorphisms often vary between different eth-
nic groups, further studies are needed to clarify the associ-
ation of the EGFR polymorphisms with the risk of lung
cancer in diverse ethnic populations.
Abbreviations used
EGFR, epidermal growth factor receptor; SNP, single
nucleotide polymorphisms; LD, linkage disequilibrium;
OR, odds ratio; CI, confidence interval; Pc-value, Bonfer-
roni corrected P-value.
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